<DOC>
	<DOCNO>NCT00006721</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop cancer cell divide stop grow die . Monoclonal antibody locate tumor cell either kill deliver radioactive tumor-killing substance without harm normal cell . It yet know monoclonal antibody plus combination chemotherapy regimen effective treat non-Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial compare 2 different monoclonal antibody give together combination chemotherapy see well work treat patient newly-diagnosed non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>S0016 Combination Chemotherapy With Monoclonal Antibody Therapy Treating Patients With Newly Diagnosed Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare progression-free survival overall survival patient newly diagnose follicular non-Hodgkin 's lymphoma treat cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) without either rituximab iodine I 131 tositumomab ( monoclonal antibody anti-B1 ) . ( CHOP chemotherapy alone arm close accrual 12/15/02 ) - Compare response rate patient treat regimen . - Compare toxic effect regimens patient . - Compare molecular remission rate patient population treat regimen . - Determine incidence time development human anti-mouse antibody positivity . OUTLINE : This randomize , multicenter study . Patients stratify accord whether microglobulin great upper limit normal ( yes v ) . Patients randomize 1 3 treatment arm . ( Arm I close accrual 12/15/02 ) - Arm I ( CHOP ) : Patients receive cyclophosphamide IV 15 minute , doxorubicin IV 5-20 minute , vincristine IV 5-15 minute day 1 . Patients also receive oral prednisone daily day 1-5 . Treatment continue every 21 day 6 course absence disease progression unacceptable toxicity . ( Arm I close accrual 12/15/02 ) - Arm II ( CHOP + rituximab ) : Patients receive cyclophosphamide IV 15 minute , doxorubicin IV 5-20 minute , vincristine IV 5-15 minute day 8 , 29 , 50 , 71 , 92 , 113 . Patients also receive oral prednisone daily day 8-12 , 29-33 , 50-54 , 71-75 , 113-117 rituximab IV 4-6 hour day 1 , 6 , 48 , 90 , 134 , 141 . - Arm III ( CHOP + tositumomab ) : Patients receive chemotherapy arm I tositumomab ( monoclonal antibody anti-B1 ) IV 1 hour follow iodine I 131 tositumomab IV 20 minute day 134 141 . Patients follow day 200 , 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : Approximately 500 patient ( 250 per treatment arm ) accrue study within 5.5 year . ( Arm I close accrual 12/15/02 )</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm previously untreated bulky stage II stage III IV follicular nonHodgkin 's lymphoma Grade IIII disease Cluster differentiation antigen 20 ( CD20 ) antigen positive Fewer 5,000/mm^3 circulate lymphoid cell white blood cell ( WBC ) differential count Bidimensionally measurable disease Bone marrow aspiration biopsy within past 42 day No clinical evidence central nervous system ( CNS ) involvement lymphoma PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Granulocyte count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Not specify Renal : Not specify Cardiovascular : No impaired cardiac status , include : Severe coronary artery disease Cardiomyopathy Congestive heart failure Serious arrhythmia Ejection fraction least low limit normal Multi Gated Acquisition Scan ( MUGA ) 2D echocardiogram questionable cardiac history Other : No hypersensitivity iodine Not pregnant nursing Fertile patient must use effective contraception 6 month study participation HIV negative No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No prior monoclonal antibody cancer Chemotherapy : No prior chemotherapy lymphoma Prior prednisone nonlymphoma related illness allow Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy lymphoma Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
</DOC>